Ozempic Gastroparesis: Who May Need Monitoring in Florida?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Targeted Legal Inquiry

If you're experiencing persistent nausea, vomiting, or abdominal pain after taking Ozempic, you may be wondering whether the medication could be causing gastroparesis. The long history of public health education has established a foundation for understanding medication risks, but the specific concern of delayed gastric emptying tied to GLP-1 agonists is a more recent focus. This page explains how clinicians diagnose and monitor this potential side effect.

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which is a known mechanism that can contribute to gastrointestinal adverse effects. Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, abdominal pain, and early satiety. The clinical presentation of gastroparesis overlaps with common gastrointestinal adverse reactions reported with Ozempic use. Clinical trial data from the Ozempic prescribing information document that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic compared to placebo. In the pool of placebo-controlled trials, nausea was reported in 15.8% of patients on Ozempic 0.5 mg and 20.3% on Ozempic 1 mg, versus 6.1% on placebo. Vomiting occurred in 5.0% and 9.2% of patients on the 0.5 mg and 1 mg doses, respectively, compared to 2.3% on placebo. Diarrhea was reported in 8.5% and 8.8% of patients on the active drug versus 1.9% on placebo. Abdominal pain occurred in 7.3% and 5.7% of patients on Ozempic versus 4.6% on placebo, and constipation was reported in 5.0% and 3.1% versus 1.5% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of these events occurred during dose escalation, and discontinuation due to gastrointestinal adverse reactions was higher with Ozempic (3.1% for 0.5 mg, 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (3.5% for 0.5 mg, 2.7% for 1 mg), eructation (2.7% for 0.5 mg, 1.1% for 1 mg), flatulence (0.4% for 0.5 mg, 1.5% for 1 mg), gastroesophageal reflux disease (1.9% for 0.5 mg, 1.5% for 1 mg), and gastritis (0.8% for 0.5 mg, 0.4% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a pattern of gastrointestinal disturbance that aligns with the symptoms of gastroparesis.

Mechanistic Link Between Ozempic and Gastroparesis

The mechanistic pathway linking Ozempic to gastroparesis involves the drug's effect on GLP-1 receptors in the gastrointestinal tract. GLP-1 receptor agonists delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to prolonged retention of gastric contents. This pharmacological effect is dose-dependent and can become clinically significant in susceptible individuals, potentially resulting in gastroparesis-like symptoms. The timeline between exposure and documented harm is variable; symptoms often emerge during dose escalation, as noted in clinical trials, but may also develop after prolonged use. The prescribing information does not specifically list gastroparesis as an adverse reaction, but the reported gastrointestinal adverse reactions encompass its clinical features. From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a key consideration. The prescribing information includes warnings about gastrointestinal adverse reactions but does not explicitly mention gastroparesis as a potential complication. This may affect the ability of patients and healthcare providers to recognize the condition early and manage it appropriately.

Legal Considerations for Florida Residents

For affected patients in Florida, attorney-related considerations include the statute of limitations for filing a product liability claim. In Florida, the statute of limitations for personal injury claims is generally four years from the date of injury, but this can vary based on the specific circumstances, such as when the injury was discovered or should have been discovered. Patients who have developed gastroparesis after using Ozempic should consult with a legal professional to understand the applicable deadlines and preserve their rights. The timeline between exposure and documented harm is critical for legal claims. Patients may experience symptoms within weeks to months of starting Ozempic, particularly during dose escalation. However, some cases may develop after longer periods of use. Medical records documenting the onset of symptoms, diagnostic evaluations (such as gastric emptying studies), and the temporal relationship to Ozempic use are essential for establishing causation. The evidence from clinical trials shows that gastrointestinal adverse reactions are common and dose-related, supporting a plausible link between Ozempic and gastroparesis. In summary, the available evidence indicates that Ozempic is associated with a range of gastrointestinal adverse reactions that overlap with the clinical presentation of gastroparesis. The mechanistic basis for this association is the drug's effect on gastric emptying. The adequacy of warnings in the prescribing information may be insufficient to alert patients and providers to the risk of gastroparesis specifically. For Florida residents affected by this condition, legal considerations include the statute of limitations, which requires timely action. Patients should seek medical evaluation for persistent gastrointestinal symptoms and consult with an attorney to discuss their legal options.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for an Ozempic gastroparesis claim in Florida?

In Florida, the statute of limitations for personal injury claims is generally four years from the date of injury. However, this can vary based on when the injury was discovered or should have been discovered. It is crucial to consult with an attorney promptly to determine the applicable deadline for your specific case.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This pharmacological effect can lead to prolonged retention of gastric contents, resulting in symptoms consistent with gastroparesis, such as nausea, vomiting, and abdominal pain. Clinical trials have reported a higher incidence of gastrointestinal adverse reactions in patients taking Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.